Dupixent® reduced eosinophilic oesophagitis symptoms by 64 percent compared to placebo and met primary endpoints in second Phase III study.
List view / Grid view
DUPIXENT (dupilumab) is an injectable prescription medicine used to treat adult patients with moderate-to-severe eczema whose disease is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. DUPIXENT can be used with or without topical corticosteroids. It is not known if DUPIXENT is safe and effective in children.
Dupixent® is the first biologic to significantly reduce itch and skin lesions in Phase III trial for prurigo nodularis.
Dupixent is the first biologic medicine to significantly reduce signs and symptoms of atopic dermatitis in children as young as six months.
The EC has approved an extension of marketing authorisation for Regeneron and Sanofi's Dupixent (dupilumab) for children aged six to 11 with severe atopic dermatitis.
In combination with inhaled corticosteroids, the monoclonal antibody Dupixent improved lung function and reduced the rate of severe asthma attacks.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis...
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
The US Food and Drug Administration (FDA) approved Sanofi and Regeneron's Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Regeneron Pharmaceuticals and Sanofi’s two placebo-controlled Phase 3 trials, evaluating dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints evaluating the extent and severity of the disease.
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
19 November 2015 | By Victoria White
The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, according to research and consulting firm GlobalData.
19 May 2015 | By Victoria White
Regeneron and Sanofi have shared positive results from an interim analysis of a pivotal Phase 2b study of dupilumab in adult patients with moderate to-severe asthma, who are uncontrolled despite treatment with inhaled corticosteroids and long-acting beta agonists (ICS/LABA).